Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022009203 - HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODY

Publication Number WO/2022/009203
Publication Date 13.01.2022
International Application No. PCT/IL2021/050830
International Filing Date 06.07.2021
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 9/24 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
24acting on glycosyl compounds (3.2)
C07K 16/40 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
Applicants
  • TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED [IL]/[IL]
  • HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. [IL]/[IL]
Inventors
  • VLODAVSKY, Israel
  • BARASH, Uri
  • WU, Liang
Agents
  • LIVNEH, Devorah N.
Priority Data
63/048,21106.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODY
(FR) ANTICORPS MONOCLONAL A54 NEUTRALISANT L’HÉPARANASE
Abstract
(EN) The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.
(FR) La présente invention concerne un anticorps monoclonal se liant à l’héparanase et neutralisant l’héparanase (IgG -1 mAb A54), y compris son épitope (HBD -II) et le mode d’interaction avec l’héparanase, une composition pharmaceutique comprenant celui-ci, et les utilisations de celui-ci, par exemple pour inhiber ou traiter une maladie ou un trouble associé à l’activité héparanase comprenant, entre autres, le cancer, l’inflammation, une infection virale, le diabète et les complications associées. La présente invention concerne en outre des polythérapies anticancéreuses, comprenant le mAb neutralisant l’héparanase et un traitement anticancéreux supplémentaire tel qu’une chimiothérapie ou un rayonnement.
Latest bibliographic data on file with the International Bureau